Key Takeaways
- Machine-perfused livers were found to be biologically younger, reversing their age by 30% compared to standard preservation methods.
- Despite the age increase when transplanted, these livers maintained a younger biological profile post-transplant.
- The high cost of perfusion raises concerns, with prices ranging from €10,000 in Germany to $80,000-$100,000 in the U.S.
Reversal of Biological Age in Livers
Researchers have made significant progress in understanding the biological aging of livers through a process known as machine perfusion. This method, which involves pumping the organs with oxygen and nutrients at a temperature of 34 degrees Celsius, has demonstrated the ability to reverse the biological age of these livers. Dr. Longchamp, a key researcher, stated that this treatment has a notable effect, leading to findings that were shared at an industry conference.
Dr. Poganik noted that when adjusting for chronological age, the difference observed in biological age due to perfusion was approximately 30%. This finding suggests that the perfusion process plays a critical role in enhancing organ viability.
Upon transplantation into recipients, the biological age of the livers typically increased due to stress factors. However, even after transplant, the perfused organs maintained a younger biological state compared to non-perfused ones. Nathanael Raschzok, a transplant surgeon from Charité Universitätsmedizin Berlin, emphasized the need for further research to understand the implications of this biological rejuvenation, particularly concerning livers from older donors. He raised the important question of how perfusion affects livers from donors aged 70 or above.
The potential application of this research points toward developing therapies that could replicate the effects of machine perfusion using pharmaceuticals. Such advancements could potentially decrease treatment costs significantly, making it feasible to treat organs before transplant without the high expense associated with current perfusion technologies. Raschzok highlighted that the current cost of perfusion is steep, costing around €10,000 in Germany and as high as $100,000 in the U.S., which can strain transplant budgets.
However, challenges remain in understanding the full benefits of this technology. Researchers faced limitations in studying liver specimens before perfusion due to procedural protocols that leave a gap in ownership of the organs between procurement and perfusion. This gap poses a challenge for comprehensive analysis, as Dr. Yeh noted that the timing of when an organ is considered under hospital purview impacts research opportunities.
In summary, while the findings regarding machine-perfused livers are promising, further exploration is necessary to fully understand the ramifications for liver transplantation, especially concerning older donor organs. The implications for improving organ viability through biological age reversal could pave the way for more effective transplant practices in the future.
The content above is a summary. For more details, see the source article.